Elicio Therapeutics, Inc. (ELTX)
NASDAQ: ELTX · Real-Time Price · USD
1.900
-0.040 (-2.06%)
Oct 23, 2026, 4:00 PM EDT - Market closed
Company Description
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer.
Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations.
The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide treatment for mutant b-raf murine sarcoma viral oncogene homolog B1-(BRAF) driven cancers, and ELI-008, a multivalent lymph node-targeted AMP peptide vaccine in preclinical studies for the treatment of mutated tumor protein p53-expressing cancers.
Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts.
Elicio Therapeutics, Inc.
| Country | United States |
| Founded | 2011 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 33 |
| CEO | Robert Connelly |
Contact Details
Address: 451 D Street, 5th Floor Boston, Massachusetts 02210 United States | |
| Phone | 857 209 0050 |
| Website | elicio.com |
Stock Details
| Ticker Symbol | ELTX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $0.00 |
| CIK Code | 0001601485 |
| CUSIP Number | 28657F103 |
| ISIN Number | US28657F1030 |
| Employer ID | 11-3430072 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Robert T. Connelly | Chief Executive Officer, President and Director |
| Dr. Allen Richard Nissenson F.A.S.N., FACP, M.D. | Founder and Independent Director |
| Dr. Preetam Shah M.B.A., Ph.D. | Chief Strategy and Financial Officer and Treasurer |
| Dr. Christopher M. Haqq M.D., Ph.D. | Executive Vice President, Head of Research and Development and Chief Medical Officer |
| Dr. Darrell J. Irvine Ph.D. | Co-Founder, Consultant, Board Observer and Chairman of Scientific Advisory Board |
| Marc J. Wolfgang M.S. | Chief Technology Officer |
| Dr. Peter DeMuth Ph.D. | Chief Scientific Officer |
| Megan C. Filoon | General Counsel, Secretary and Compliance Officer |
| Esther Welkowsky | Senior Vice President of Clinical Development |
| Joy Seymour | Senior Vice President and Head of Regulatory Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 9, 2026 | DEF 14A | Other definitive proxy statements |
| Sep 14, 2026 | 8-K | Current Report |
| Aug 13, 2026 | 10-Q | Quarterly Report |
| Aug 13, 2026 | 8-K | Current Report |
| Jul 16, 2026 | SCHEDULE 13G | Filing |
| Jul 8, 2026 | SCHEDULE 13G/A | Filing |
| Jul 2, 2026 | 424B5 | Filing |
| Jul 2, 2026 | 8-K | Current Report |
| Jun 24, 2026 | 8-K | Current Report |
| Jun 17, 2026 | 8-K | Current Report |